Clarity Pharmaceuticals (ASX:CU6) signed a copper-64 isotope supply agreement with the University of Queensland's Australian Institute for Biotechnology and Nanotechnology, according to a Wednesday Australian bourse filing.
The supply agreement will support the firm's clinical trials with copper-64 SAR-bisPSMA imaging agent in Australia for prostate cancer patients. It will also support the rollout of two theranostic preclinical programs, SAR-bisFAP and SAR-trastuzumab.
It will expand the manufacturing capability of the agent for the phase three CLARIFY and AMPLIFY registrational trials in Australia, an ongoing investigator-initiated trial, as well as the Co-PSMA and SECuRE theranostic trials.
The firm's shares rose 2% in recent trading on Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.